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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S131outside the skeletal tissue. HO is thought to result from aberrant dif-
ferentiation of osteogenic progenitors within skeletal muscle. However
the precise origin of HO is still unclear. Skeletal muscle contains two
kinds of progenitor cells, myogenic progenitors and mesenchymal
progenitors. We have identiﬁed PDGFRaþ mesenchymal progenitors in
mouse muscle interstitium and the PDGFRaþ mesenchymal progeni-
tors showed osteogenic differentiation in response to BMP stimulation,
while another report showed that these cells did not differentiate into
osteogenic cells when stimulated with dexamethasone, b-glycer-
ophosphate and ascorbic acid. These results suggest that HO may be
derived from PDGFRaþ progenitors in skeletal muscle. The purpose of
this study is to examine the localization of PDGFRaþ mesenchymal
progenitors in human HO and bone forming capacity of human skeletal
muscle-derived progenitors in vitro and vivo.
Methods: Immunohistological staining of human HO: HO sample
was obtained by thirty ﬁve-year-old manwho had femoral fracture and
subarachnoid hemorrhage by trafﬁc accident and was treated by open
reduction and internal ﬁxation. X-ray analysis showed that HO was
observed around the left hip joint, especially in rectus femoris muscle
and vastus medialis muscle. We examined human skeletal muscle
sample with HO using immunohistological staining. Osteogenic dif-
ferentiation potential of human skeletal muscle-derived progeni-
tors in vitro: In this study, we used the human muscular tissue of
patients with osteoarthritis of hip, after informed consent was obtained
at the time of hip surgery from ten patients. Experiments using human
samples were approved by the Ethical Review Board for Clinical Studies
at Fujita Health University. Trimmedmuscles wereminced and digested
with 0.2% type II collagenase for 30 min at 37C. After enzymatic
digestion of human skeletal muscle, CD56þ cells and PDGFRaþ cells
were isolated by using ﬂow cytometry. Cells were seeded at a density of
4.2 x 10x cells/cm z and incubated at 37C in 5% CO2 and 21% O2. At 50–
70% conﬂuency, osteogenesis was induced using osteogenic differ-
entiation medium consisting of 10% FBS-aMEM supplemented with
dexamethasone, ascorbate-phosphate, and b-glycerophosphate. The
judgement of osteogenesis was alkaline phosphatase (ALP) staining and
alizarin red S staining. Bone forming capacity of human skeletal
muscle-derived progenitors in vivo: To study the capacity of human
skeletal muscle-derived cells to form bone, cells (1 x 106 cells/ block)
were loaded onto PLGA- hydroxyapatite composite blocks. Implants
were removed after 8 weeks and ﬁxed with 10% formaldehyde, then
embedded in parafﬁn stained using hematoxylin-eosin staining and
immune staining.
Results: Immunohistological staining of human HO: At the staining
of HO sample, many PDGFRaþ cells were found in proximity to ectop-
ically formed bone. In contrast, we did not observe CD56þ cells around
ectopic bone. Osteogenic differentiation potential of human skeletal
muscle-derived progenitors in vitro: Both PDGFRaþ cells and CD56þ
cells became positive for ALP at an early stage of differentiation, while
alizarin red S staining of both cell types did not become positive until 14
days after osteogenic induction. There was no signiﬁcant difference
between them. Bone forming capacity of human skeletal muscle-
derived progenitors in vivo: PDGFRaþ cells showed successful
engraftment and had formed bone-like tissue. Structures histologically
resembling medullary cavities were observed, and multinucleated giant
cells detected at the edges of cavities. In contrast, CD56þ cells did not
create such tissues. Many human cells were detected in PDGFRaþ cell
implants, while only a few human cells were detected in CD56þ cell
implants.
Conclusions: PDGFRaþ cells and CD56þ cells showed comparable dif-
ferentiation potential in vitro with similar levels of ALP activity after
osteogenic differentiation. However, PDGFRaþ cells, but not CD56þ
cells, showed superior engraftment and bone-like tissue formation in
the PLGA-hydroxyapatite scaffold-based an in vivo bone formation
model, suggesting that PDGFRaþ mesenchymal progenitors residing
human skeletal muscle are the major origin of HO.
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HYDROLYZED COLLAGEN CONTRIBUTES TO OSTEOBLAST
DIFFERENTIATION IN VITRO AND SUBSEQUENT BONE HEALTH IN
VIVO
A. Daneault. Inst. Natl. de Recherche Agronomique, St Genes Champanelle,
France
Purpose: Collagen I is the main component of organic bone matrix. Its
correct synthesis, folding and degradation are crucial for bonehomeostasis. According to this pivotal role in bone structure, we
investigated the potential health beneﬁts of hydrolyzed collagen (HC)
on bone using translational approaches.
Methods & Results: Regarding the inﬂuence of HC on bone forming
cells in vitro, we ﬁrst insured the absence of cytotoxicity of HC addition
in culture media. Consistently, as compared to BSA control conditions,
HC even promoted pre-osteoblast proliferation. Then, cells were tested
for differentiation parameters in the presence of HC. HC from bovine
origin resulted in a signiﬁcantly higher alkaline phosphatase activity
after 7 days of incubation when compared to its BSA control condition.
This observation was supported by mineralization assays demonstrat-
ing that bovine HC enhanced Ca/P nodule formation in MC3T3-E1 cul-
tures. To conﬁrm these encouraging results, C3H/HeN mice were
ovariectomized (OVX) to induce bone loss and were given, in parallel,
HC enriched diets to determine whether HC intake may contribute to
bone health by preventing decrease in bone mineral density upon OVX.
Diets were designed to contain 15% casein, 17.5% casein or 15% casein
plus 2.5% HC from bovine origin.
Conclusion: As expected, OVX induced a dramatic loss of bone mineral
density. However, HC fed OVX mice exhibited a signiﬁcant higher BMD
than OVX control mice suggesting a nutritional protective effect of HC,
conﬁrming previous results and further supporting its potential bene-
ﬁts on bone health.Cartilage Biology
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IL18 IS SECRETED UPON JOINT INJURY AND IS A KEY PATHOGENIC
CYTOKINE IN MURINE OSTEOARTHRITIS
T.L. Vincent, A. Chanalaris, J. Zarebska, S. Bullers, B. Stott, A. Burleigh,
E. Paterson, F.E. Watt, J. Saklatvala. Kennedy Inst. of Rheumatology,
Oxford, United Kingdom
Purpose: Osteoarthritis requires the expression and activation of
matrix proteases that drive the degradation of the articular cartilage.
Speciﬁcally these include the aggrecanases, members of the a dis-
integrin and metalloproteinase with thrombospondin motif (ADAMTS)
family, and the collagenases, principally matrix metalloproteinases 1
and 13. IL1 is a potent inducer of ADAMTSes andMMPs in vitro, but little
evidence exists to support its role in disease in vivo. MyD88 is an
essential upstream component of the IL1 receptor (IL1R) signaling
complex, and is also utilized by other IL1R family members such as
IL18R and IL33R, and by several of the Toll like receptors (TLRs 1, 2, 4-9).
We sought to determine the MyD88-dependence of murine OA.
Methods: We investigated the role of IL1 and related cytokines in vivo
by inducing OA in mice (by destabilization of the medial meniscus,
DMM) in which the adapter protein, MyD88, or the ligands/receptors
utilising MyD88, had been deleted. Gene expression proﬁles of wild
type and knockout joints were examined 6h post surgical joint desta-
bilization. Porcine cartilage and synovium were assayed for IL18
secretion following injury in the presence or absence of the caspase
(IL18-processing enzyme) inhibitor, Z-VAD-FMK. For in vivo experi-
ments, Z-VAD-FMK was injected into wild type mice every two days
prior to (for 1 week) and following DMM surgery for a further 4 weeks.
Joints were sectioned and scored histologically. For human studies,
control synovial ﬂuid or that taken from individuals who had recently
sustained acute destabilizing injuries to the joint (largely meniscal and
cruciate ligament) were assayed for IL18 using an MBL ELISA (Nagoya,
Japan).
Results: MyD88 -/- mice were strongly protected from surgically
induced OA at 4, 8 and 12 weeks post surgery. Of the other knockout
mice tested (IL1 receptor, TLR2, TLR4, TLR7, IL33R, IL18), only IL18-/-
mice phenocopied the protection seen in MyD88-/- mice. No change
in gene expression for IL18, its receptor or the endogenous negative
regulator, IL18 binding protein, was measured in destabilized joints,
but IL18 protein was secreted by porcine synovium in vitro following
explantation injury in a caspase-dependent manner. Gene expression
in IL18-/- joints following DMM showed several genes were altered
compared to wild type joints indicating that there are IL18-depend-
ent changes in gene expression upon induction of OA. Mice treated
with the caspase inhibitor, Z-VAD-FMK showed a signiﬁcant reduc-
tion in disease severity 4 weeks post DMM compared to vehicle
treated mice. Of the human studies, IL18 was signiﬁcantly elevated in
the synovial ﬂuid of patients following acute joint injury compared to
controls.
